AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Kane Biotech Inc.

$0.02 -$0.01 (-30.08%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0.02
Day Range
$0.02$0.02
Year Range
$0.01$0.03
Market Cap
3.81M
AVG Volume
115.48K
Trailing/Forward PE
-2.05/-
PEG ratio
0.07
Dividend Yield
-
Next Earnings Date
2026-11-26
Primary Exchange
Other OTCUS
Revenue (CAD)
-500K0500K1M1.5M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Revenue (CAD) by quarter
PeriodRevenue (CAD)
26 Q28.15K
26 Q143.33K
25 Q4-21.49K
25 Q38.5K
25 Q228K
25 Q1412.51K
24 Q4125.86K
24 Q31.28M
24 Q2620.44K
24 Q151.89K
Net Income (CAD)
-5M05M10M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Net Income (CAD) by quarter
PeriodNet Income (CAD)
26 Q2-834K
26 Q1-716.67K
25 Q4-544.64K
25 Q3-607.35K
25 Q2-348.54K
25 Q1-1.22M
24 Q4-1.08M
24 Q3-605.81K
24 Q29.18M
24 Q1-1.4M
Operating Income (CAD)
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Operating Income (CAD) by quarter
PeriodOperating Income (CAD)
26 Q2-788.82K
26 Q1-679.05K
25 Q4-1.13M
25 Q3-543.43K
25 Q2-275.46K
25 Q1-1.16M
24 Q4-1.02M
24 Q3-611.31K
24 Q2-1.1M
24 Q1-1.19M
EBITDA (CAD)
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF EBITDA (CAD) by quarter
PeriodEBITDA (CAD)
26 Q2-775.77K
26 Q1-660K
25 Q4-1.14M
25 Q3-499.26K
25 Q2-197.46K
25 Q1-1.11M
24 Q4-956.95K
24 Q3-567.46K
24 Q2-1.06M
24 Q1-1.12M
Cash Flows (CAD)
-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Cash Flows (CAD) by quarter
PeriodCash Flows (CAD)
26 Q2-634.59K
26 Q1-486.9K
25 Q4-582.74K
25 Q3-703.83K
25 Q2-822.56K
25 Q1-1.15M
24 Q4-461.11K
24 Q3-546.58K
24 Q2-2.2M
24 Q1-991.36K
EPS (CAD)
-0.0200.020.040.0624 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF EPS (CAD) by quarter
PeriodEPS (CAD)
26 Q2-0
26 Q1-0
25 Q4-0
25 Q3-0
25 Q2-0
25 Q1-0.01
24 Q4-0.01
24 Q3-0
24 Q20.06
24 Q1-0.01
Expenses (CAD)
-500K0500K1M1.5MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Expenses (CAD) by quarter
PeriodExpenses (CAD)
26 Q2777.22K
26 Q1666.02K
25 Q4783.18K
25 Q3543.92K
25 Q2279.59K
25 Q11.25M
24 Q4974.71K
24 Q31.18M
24 Q21.5M
24 Q11.22M
Cash & Debt (CAD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Cash & Debt (CAD) by quarter
PeriodCash & Debt (CAD)
26 Q2855.1K
26 Q1396.08K
25 Q4900.96K
25 Q3939.06K
25 Q21.61M
25 Q1493.58K
24 Q4358.81K
24 Q3544.38K
24 Q21.01M
24 Q1826.7K
Debt ratios
-3-2-1024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Debt ratios by quarter
PeriodDebt ratios
26 Q2-0.36
26 Q1-0.61
25 Q4-0.48
25 Q3-0.49
25 Q2-0.35
25 Q1-0.43
24 Q4-0.49
24 Q3-0.44
24 Q2-0.31
24 Q1-2.15
Margins
-250%0%250%500%750%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Margins by quarter
PeriodMargins
26 Q2-142.49%
26 Q1-52.99%
25 Q4721.47%
25 Q3-60.34%
25 Q2-162.61%
25 Q110.29%
24 Q4-69.29%
24 Q343.56%
24 Q258.1%
24 Q1-27.1%
Return on Capital
-1500%-1000%-500%0%500%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Return on Capital by quarter
PeriodReturn on Capital
26 Q283.88%
26 Q150.39%
25 Q473.01%
25 Q376.55%
25 Q2148.32%
25 Q1107.45%
24 Q466.47%
24 Q387.97%
24 Q2-1272.35%
24 Q114.64%
Shares Outstanding
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Shares Outstanding by quarter
PeriodShares Outstanding
26 Q2205.06M
26 Q1181.86M
25 Q4162.22M
25 Q3167.35M
25 Q2163.03M
25 Q1150.06M
24 Q4141.98M
24 Q3133.79M
24 Q2132.82M
24 Q1131.84M
Book Value Per Share (CAD)
-0.08-0.06-0.04-0.02024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Book Value Per Share (CAD) by quarter
PeriodBook Value Per Share (CAD)
26 Q2-0
26 Q1-0.01
25 Q4-0
25 Q3-0
25 Q2-0
25 Q1-0.01
24 Q4-0.01
24 Q3-0.01
24 Q2-0.01
24 Q1-0.07
Total Assets (CAD)
02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KNBIF Total Assets (CAD) by quarter
PeriodTotal Assets (CAD)
26 Q22.23M
26 Q11.82M
25 Q42.73M
25 Q32.74M
25 Q23.81M
25 Q12.76M
24 Q42.49M
24 Q33.91M
24 Q24.07M
24 Q15.8M
PE Ratio
01234med 2.15Oct 24Dec 24Feb 25Apr 25Jun 25Aug 25Sep 25
KNBIF PE Ratio by quarter
PeriodPE Ratio
Sep 251.09
Sep 250.9
Sep 250.91
Sep 250.94
Aug 250.9
Aug 250.9
Aug 250.97
Aug 251
Aug 250.96
Jul 250.95
Jul 250.95
Jul 251.15
Jul 251.14
Jun 251.11
Jun 251.44
Jun 251.43
Jun 251.18
May 251.15
May 251.25
May 251.4
May 251.88
May 251.86
Apr 252.07
Apr 252.15
Apr 252.26
Apr 252.33
Mar 252.14
Mar 252.18
Mar 252.25
Mar 252.06
Feb 252.14
Feb 252.37
Feb 252.41
Feb 252.48
Jan 252.54
Jan 252.56
Jan 252.35
Jan 252.49
Jan 252.49
Dec 242.47
Dec 242.47
Dec 242.9
Dec 242.89
Nov 243.1
Nov 242.73
Nov 242.75
Nov 242.71
Nov 243.45
Oct 243.43
Oct 243.41
Oct 243.43
Oct 243.38
Free Cash Flow Yield
-80%-60%-40%-20%med -49.95%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNBIF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-55.68%
Sep 26-61.99%
Aug 26-55.51%
Aug 26-47.36%
Aug 26-46.99%
Aug 26-58.87%
Jul 26-50.54%
Jul 26-55.97%
Jul 26-56.26%
Jul 26-56.05%
Jul 26-51.62%
Jun 26-71.85%
Jun 26-56.82%
Jun 26-57.43%
Jun 26-66.09%
May 26-66.81%
May 26-66.68%
May 26-60.9%
May 26-60.94%
May 26-44.66%
Apr 26-55.2%
Apr 26-68.55%
Apr 26-68.45%
Apr 26-65.59%
Mar 26-61.6%
Mar 26-62.38%
Mar 26-53.15%
Mar 26-51.19%
Feb 26-50.15%
Feb 26-50.02%
Feb 26-47.47%
Feb 26-46.47%
Jan 26-46.74%
Jan 26-44.21%
Jan 26-47.09%
Jan 26-49.26%
Jan 26-51.32%
Dec 25-50.25%
Dec 25-49.79%
Dec 25-49.89%
Dec 25-52.91%
Nov 25-52.32%
Nov 25-51.85%
Nov 25-49.37%
Nov 25-59.68%
Oct 25-45%
Oct 25-45.03%
Oct 25-44.95%
Oct 25-39.8%
Oct 25-39.95%
Sep 25-63.54%
Sep 25-77.12%
Sep 25-76.72%
Sep 25-74.12%
Aug 25-77.39%
Aug 25-76.93%
Aug 25-71.28%
Aug 25-69.24%
Aug 25-72.65%
Jul 25-73.13%
Jul 25-73.27%
Jul 25-60.65%
Jul 25-61.1%
Jun 25-61.82%
Jun 25-47.78%
Jun 25-48.32%
Jun 25-58.27%
May 25-60.01%
May 25-55.13%
May 25-49.28%
May 25-36.69%
May 25-37%
Apr 25-33.29%
Apr 25-32.07%
Apr 25-30.5%
Apr 25-29.55%
Mar 25-43.79%
Mar 25-43.03%
Mar 25-41.75%
Mar 25-45.47%
Feb 25-43.8%
Feb 25-39.65%
Feb 25-38.94%
Feb 25-37.93%
Jan 25-37.02%
Jan 25-36.6%
Jan 25-39.89%
Jan 25-37.68%
Jan 25-37.76%
Dec 24-45.18%
Dec 24-45.27%
Dec 24-38.49%
Dec 24-38.7%
Nov 24-36.06%
Nov 24-40.89%
Nov 24-40.66%
Nov 24-41.18%
Nov 24-32.39%
Oct 24-32.52%
Oct 24-32.74%
Price to Sales
0255075100med 7.47Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
KNBIF Price to Sales by quarter
PeriodPrice to Sales
Sep 2679.92
Sep 2671.79
Aug 2680.17
Aug 2693.96
Aug 2694.71
Aug 2675.59
Jul 2688.06
Jul 2679.51
Jul 2679.1
Jul 2679.4
Jul 2686.2
Jun 2610.61
Jun 2613.41
Jun 2613.27
Jun 2611.53
May 2611.4
May 2611.43
May 2612.51
May 2612.5
May 2617.06
Apr 2613.8
Apr 2611.12
Apr 2611.13
Apr 2611.62
Mar 268.86
Mar 268.75
Mar 2610.26
Mar 2610.66
Feb 2610.88
Feb 2610.91
Feb 2611.49
Feb 2611.74
Jan 2611.67
Jan 2612.34
Jan 2611.58
Jan 2611.07
Jan 2610.63
Dec 253.21
Dec 253.24
Dec 253.23
Dec 253.04
Nov 253.08
Nov 253.11
Nov 253.26
Nov 252.7
Oct 253.58
Oct 253.58
Oct 253.58
Oct 254.05
Oct 254.03
Sep 252.81
Sep 252.31
Sep 252.33
Sep 252.41
Aug 252.31
Aug 252.32
Aug 252.5
Aug 252.58
Aug 252.46
Jul 252.44
Jul 252.44
Jul 252.94
Jul 252.92
Jun 253.27
Jun 254.23
Jun 254.18
Jun 253.46
May 253.36
May 253.66
May 254.1
May 255.5
May 255.46
Apr 256.07
Apr 256.3
Apr 256.62
Apr 256.83
Mar 256.37
Mar 256.49
Mar 256.69
Mar 256.14
Feb 256.37
Feb 257.04
Feb 257.17
Feb 257.36
Jan 257.54
Jan 257.62
Jan 257
Jan 257.41
Jan 257.39
Dec 248.89
Dec 248.88
Dec 2410.44
Dec 2410.38
Nov 2411.15
Nov 249.83
Nov 249.88
Nov 249.76
Nov 2412.41
Oct 2412.36
Oct 2412.28
Price to Book
050100150med 25.52Jun 20Oct 20Jan 21Apr 21Aug 21Nov 21Sep 23
KNBIF Price to Book by quarter
PeriodPrice to Book
Sep 231.21
Sep 231.3
Sep 231.12
Sep 231.39
Aug 231.52
Aug 231.52
Aug 231.5
Aug 231.5
Jul 231.41
Jul 231.56
Jul 231.45
Dec 2158.02
Dec 2158.42
Dec 2157.04
Dec 2158.69
Nov 2163.65
Nov 2162.9
Nov 2159.43
Nov 2154.54
Oct 2158.85
Oct 2157.09
Oct 2160.53
Oct 2161.06
Oct 2166.04
Sep 2162.08
Sep 2162.5
Sep 2156.38
Sep 2157.71
Aug 2155.03
Aug 2158.19
Aug 2159.45
Aug 2158.81
Jul 2160.94
Jul 2161.17
Jul 2159.94
Jul 2158.08
Jul 2158.38
Jun 2116.16
Jun 2117.43
Jun 2117.77
Jun 2117.65
May 2119.11
May 2118.79
May 2119.53
May 2120.17
Apr 2122.32
Apr 2119.15
Apr 2118.82
Apr 2116.96
Apr 2117.15
Mar 218.85
Mar 218.19
Mar 217.26
Mar 217.48
Feb 217.36
Feb 216.95
Feb 217.25
Feb 216.67
Jan 216.95
Jan 217.3
Jan 217.22
Jan 217.89
Dec 207.88
Dec 20101.7
Dec 2097.52
Dec 20101.11
Dec 20102.67
Nov 20112.83
Nov 20102.66
Nov 20109.45
Nov 2089.37
Oct 2091.16
Oct 20104.19
Oct 20117.02
Oct 20106.6
Oct 20119.74
Sep 2027.23
Sep 2028.02
Sep 2027.97
Sep 2028.02
Aug 2026.64
Aug 2027.96
Aug 2026.19
Aug 2028.92
Jul 2025.85
Jul 2027.73
Jul 2029.05
Jul 2025.2
Jul 2021.84
Jun 2016.93
Jun 2017.87
Jun 2015.17
Jun 2014.14
May 2014.51
May 2014.57
May 2014.94
May 2014.23
May 2013.08
Apr 2013.42
Apr 2013.33
Kane Biotech Inc.
KNBIF
Stockpicker

Video analysis: KNBIF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: KNBIF

Kane Biotech to Host Commercial Update Webcast on September 16

globenewswire.com · 9 Sep 2026

Kane Biotech to Host Commercial Update Webcast on September 16

Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities

Kane Biotech Announces Second Quarter 2026 Financial Results

globenewswire.com · 27 Aug 2026

Kane Biotech Announces Second Quarter 2026 Financial Results

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Kane Biotech Announces Engagement of DNA Advisors

globenewswire.com · 5 Aug 2026

Kane Biotech Announces Engagement of DNA Advisors

DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives

Kane Biotech Announces Results of Annual and Special Meeting of Shareholders

globenewswire.com · 2 Jul 2026

Kane Biotech Announces Results of Annual and Special Meeting of Shareholders

WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.

Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com · 24 Jun 2026

Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.